← Back to Search

Stem Cell Therapy

Autologous SVF for Vocal Fold Scarring

Phase 1
Led By Amy Rutt, DO
Research Sponsored by Shane A. Shapiro
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject's age between 18 and < 80-years-old
Unilateral or Bilateral vocal fold scarring
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 1, and months 1, 3, 6, 9, 12, and 24
Awards & highlights

Study Summary

This trial will study whether fat from a patient's stomach or hips can be used to heal vocal cord scars.

Who is the study for?
This trial is for adults aged 18-65 with vocal fold scarring, either from surgery or congenital causes. Participants must have had the scar for at least a year and experience significant voice handicap. Women of childbearing age should test negative for pregnancy and use contraception. Those with anesthesia risks, bleeding disorders, active infections, recent cancer treatments, COPD, kidney disease, stroke history or severe heart issues can't join.Check my eligibility
What is being tested?
The study tests if SVF cells taken from a person's own fat tissue can repair damaged vocal cords. The SVF is harvested from the patient's stomach or hips under anesthesia to see if it improves their voice quality by healing the scars on their vocal folds.See study design
What are the potential side effects?
Potential side effects may include reactions to anesthesia, discomfort at the extraction site (stomach/hips), infection risk increase due to invasive procedures involved in harvesting and injecting SVF cells into the vocal folds.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am between 18 and 79 years old.
I have scarring on one or both of my vocal cords.
My vocal cords are scarred or I've had surgery on them.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 1, and months 1, 3, 6, 9, 12, and 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 1, and months 1, 3, 6, 9, 12, and 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse events post SVF administration
Secondary outcome measures
Voice handicap Index

Trial Design

1Treatment groups
Experimental Treatment
Group I: SVF for treating scarred vocal foldsExperimental Treatment1 Intervention
Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.

Find a Location

Who is running the clinical trial?

Shane A. ShapiroLead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
Amy Rutt, DOPrincipal InvestigatorMayo Clinic

Media Library

Autologous adipose derived SVF (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05354544 — Phase 1
Vocal Fold Scarring Research Study Groups: SVF for treating scarred vocal folds
Vocal Fold Scarring Clinical Trial 2023: Autologous adipose derived SVF Highlights & Side Effects. Trial Name: NCT05354544 — Phase 1
Autologous adipose derived SVF (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05354544 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities to enroll in this experiment?

"As per the information hosted on clinicaltrials.gov, no new participants are required for this trial at present. First published on November 1st 2022 and last updated in August of the same year; while there is no recruitment taking place, a separate medical study has opened up signups recently."

Answered by AI

Who is most suitable for inclusion in this clinical investigation?

"This clinical trial is seeking 12 individuals, aged 18 to 65 with vocal fold scars. Additionally, these patients must have a voice handicap index of at least 60/120 and the scarring must be scored based on laryngoscopic examination (Type I-IV). Informed consent from each participant is needed alongside verification that no woman of childbearing age are pregnant or will become so 4 months prior to and post SVF administration."

Answered by AI

How does Autologous adipose derived SVF affect patient safety?

"Autologous adipose derived SVF is estimated to have a safety score of 1 due to the limited evidence supporting its efficacy and lack of data regarding its potential risks, as this is currently just in Phase 1."

Answered by AI

Does this clinical trial have an age restriction, and if so what is the upper limit?

"As outlined in the study's enrollment criteria, only those individuals aged between 18 and 65 are eligible to take part."

Answered by AI

Who else is applying?

What state do they live in?
How old are they?
18 - 65
What site did they apply to?
Mayo Clinic in Arizona
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
~3 spots leftby May 2025